DDrare: Database of Drug Development for Rare Diseases

156. レット症候群
［臨床試験数：36，薬物数：49（DrugBank：19），標的遺伝子数：77，標的パスウェイ数：112］

Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ANA001XHCl (Syntagon) or VEXA-04 (Patheon); ANAVEX2-73; ANAVEX2-73 (blarcamesine); ANAVEX2-73 oral liquid; Acetate; Administration of a high dose of desipramine; Administration of a low dose of desipramine; Alpha-tocotrienol quinone; Blarcamesine; CANNABIDIOL; CBD; CBD - Oral Solution, is known as Epidyolex, and is the approved name; CBD Oral solution, is known as Epidyolex and is the approved name in the EU; Cannabidiol; Cannabidiol (CBD); Creatine; Creatine monohydrate; Desipramine; Dextromethorphan; Donepezil; Donepezil hydrochloride; EMD 128130; EPI-743; Epidyolex; Epidyolex and is the approved name in the EU; Fingolimod; Fingolimod (FTY720); GWP42003-P; Glatiramer; Glatiramer Acetate; Glatiramer Acetate (Copaxone®); Human insulin; Ketamine; Lactobacillus plantarum; Lovastatin; NNZ-2566; Probiotic-Lactobacillus plantarum PS128; Recombinant Human Insulin Growth Factor 1 (rhIGF-1); Rett-T; RhIGF-1; Risperidone; SARIZOTAN HYDROCHLORIDE; Sarizotan; Sarizotan hydrochloride; Tocotrienol; Topiramate; Tridecanoic Acid; Triheptanoin; Trofinetide

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02023424 (ClinicalTrials.gov)	January 2014	23/12/2013	An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome	An Open Label, Exploratory Study to Investigate the Treatment Effect og Glatiramer Acetate (Copaxone ®) on Girls Woth Rett Syndrome	Rett Syndrome	Drug: Glatiramer Acetate (Copaxone®)	Sheba Medical Center	NULL	Recruiting	6 Years	15 Years	Female	10	Phase 1	Israel
2	NCT02153723 (ClinicalTrials.gov)	August 2013	26/5/2014	Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)	Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)	Rett Syndrome	Drug: Glatiramer Acetate	Montefiore Medical Center	Rett Syndrome Research Trust	Completed	10 Years	N/A	Female	10	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02023424
(ClinicalTrials.gov)

January 2014

23/12/2013

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

An Open Label, Exploratory Study to Investigate the Treatment Effect og Glatiramer Acetate (Copaxone ®) on Girls Woth Rett Syndrome

Rett Syndrome

Drug: Glatiramer Acetate (Copaxone®)

Sheba Medical Center

NULL

Recruiting

6 Years

15 Years

Female

Phase 1

Israel

NCT02153723
(ClinicalTrials.gov)

August 2013

26/5/2014

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Rett Syndrome

Drug: Glatiramer Acetate

Montefiore Medical Center

Rett Syndrome Research Trust

Completed

10 Years

N/A

Female

Phase 2

United States